(MENAFN – EIN Presswire) https://img.einpresswire.com/large/168611/dr-davita-danesh-of-concierge.png#940×788
Dr. Davita Danesh of Concierge Dentistry
Dr. Jay Grossman
“She has extensive experience with cosmetic dentistry, as well as pediatric dentistry.” – Dr. Jay Grossman
LOS ANGELES, CA, US, December 3, 2020 /[To enable links contact MENAFN] EINPresswire.com/ — Winner of the Best of Los Angeles Award – ‘Best Dentist – 2020’ , [To enable links contact MENAFN] Dr. Jay Grossman and his [To enable links contact MENAFN] Concierge Dentistry team are thrilled to welcome Dr. Davita Danesh to their practice in Brentwood, CA. Since 1991, Concierge Dentistry’s mission has been to deliver the finest dental care available. Using state-of-the-art dental technology, their office provides modern imaging capabilities that allow you to clearly see the reasons for procedures and the intended results.
Dr. Danesh, a native Angelino, did her undergraduate training at UCLA, and her dental training at USC. “Dr. Danesh’s extensive experience with cosmetic dentistry, as well as pediatric dentistry will be of incredible benefit to our team and patients”, states Dr. Grossman.
Professor at UCLA College of Dentistry and Professor at NYU College of Dentistry, Dr. Grossman believes in delivering ultra-high-level care with state-of-the-art equipment and techniques. He has helped over 10,000 children and adults enjoy more beautiful smiles and greater self-confidence. He states, “We recognize that patients are individuals with different goals and needs, and we strive to provide a soothing and educational environment where extraordinary results are realized.”
In partnership with Dr. Grossman’s years of experience, Dr. Davita Danesh will surely contribute to the excellence that Concierge Dentistry stands behind, and excel in her new practice. Dr. Grossman expresses his enthusiasm by stating, “We are very excited to welcome her to our practice”.
Dr. Jay Grossman ([To enable links contact MENAFN] ) has a concierge dental practice in the Brentwood neighborhood of West Los Angeles since 1991 with several specialists offering “continuity of care”, all specialties under one roof. He is a graduate of NYU College of Dentistry as well as a former Lieutenant in the United States Navy Dental Corps. He is a current Professor at UCLA College of Dentistry and Professor at NYU College of Dentistry and a former Professor at Western University College of Dental Medicine. Dr. Grossman is a speaker on the national stage, and the founder of Homeless Not Toothless, an organization that has donated over $5 million in free dental care to over 60,000 homeless Veterans and foster children.
Dr. Jay Grossman and his Concierge Dentistry team’s goal has always been simple: to deliver the finest dental care available. Using state-of-the-art dental technology, they have provided modern imaging capabilities that allow their patients to clearly see the reasons for procedures and the intended results. They recognize that patients are individuals with different goals and needs, and they strive to provide a soothing and educational environment where extraordinary results are realized.
[To enable links contact MENAFN]
11980 San Vicente Blvd #507
Los Angeles, CA 90049
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
Novocure (NASDAQ: NVCR) today announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are electric fields that disrupt cancer cell division.
“It is our goal to establish NYU as a center for Tumor Treating Fields research and development based on the academic interests of the Department of Radiation Oncology and its collaborators,” said Dr. Erik Sulman, co-director of the Brain and Spine Tumor Center at NYU Langone’s Perlmutter Cancer Center. “This partnership will help bring us closer to our goal through the development of preclinical and clinical shared platforms, and facilitate rapid clinical trial development.”
Research to be conducted is designed to further the understanding of the interaction between Tumor Treating Fields and radiation therapy, to study Tumor Treating Fields in combination with various pharmacological agents, and to identify new indications for use. This translational research is intended to deepen the understanding of Tumor Treating Fields’ effects on cancer and to fuel development of new treatment strategies.
“We are excited to partner with a leading U.S. academic institution and look forward to working with NYU’s top researchers,” said William Doyle, Novocure’s Executive Chairman. “We believe that collaborations with leading academic research centers signify growing interest in Tumor Treating Fields across the scientific community and advance our mission to extend survival in some of the most aggressive forms of cancers.”
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields therapy uses electric fields to disrupt cancer cell division. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005211/en/